These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 12128114)

  • 1. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer.
    Robnett TJ; Whittington R; Malkowicz SB; Brereton HD; Van Arsdalen K; Drach G; Wein AJ
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1146-51. PubMed ID: 12128114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer.
    Whittington R; Malkowicz SB; Machtay M; Van Arsdalen K; Barnes MM; Broderick GA; Wein AJ
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):673-80. PubMed ID: 9336149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hormonal and radiation therapy for lymph node-positive prostate cancer.
    Whittington R; Malkowicz B; Barnes MM; Broderick GA; Van Arsdalen K; Dougherty MJ; Wein AJ
    Urology; 1995 Aug; 46(2):213-9. PubMed ID: 7542824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?
    Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V
    Tumori; 2004; 90(2):201-7. PubMed ID: 15237583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer.
    Eulau SM; Tate DJ; Stamey TA; Bagshaw MA; Hancock SL
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):735-40. PubMed ID: 9652832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
    Hung AY; Levy L; Kuban DA
    Cancer J; 2002; 8(6):440-4. PubMed ID: 12500852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate.
    Perez CA; Michalski J; Brown KC; Lockett MA
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):573-84. PubMed ID: 8948341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy with or without androgen deprivation in the treatment of localized adenocarcinoma of the prostate.
    Arcangeli G; Saracino B; Micheli A; D'Angelo L; Pansadoro V; Cruciani E; Marchetti P
    Am J Clin Oncol; 1998 Feb; 21(1):1-5. PubMed ID: 9499247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.
    Lawton CA; Winter K; Grignon D; Pilepich MV
    J Clin Oncol; 2005 Feb; 23(4):800-7. PubMed ID: 15681524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
    Anderson PR; Hanlon AL; Movsas B; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1025-30. PubMed ID: 9392540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study.
    Pommier P; Chabaud S; Lagrange JL; Richaud P; Le Prise E; Wagner JP; Azria D; Beckendorf V; Suchaud JP; Bernier V; Perol D; Carrie C
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):759-769. PubMed ID: 27788949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS; Butler WM; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.